Market Cap 17,000.00
Revenue (ttm) 0.00
Net Income (ttm) -640,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.08
Volume 8,800
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 165.77M
Stochastic %K N/A
Beta -27.23
Analysts Strong Buy
Price Target N/A

Company Profile

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures...

Industry: Biotechnology
Sector: Healthcare
Phone: 973 557 8914
Address:
10 High Court, Little Falls, United States
Latest News on RGIN
No data available.